Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning. Once compromised by inflammation, the immune system loses its capacity to recognize antigens and dependably defend the body against disease and illness.

When COVID-19 invades humans, it causes an immune-storm (cytokine-storm) that can directly damage the organ(s), leading to death. The virus is an antigen - a trigger - but it is not the actual reason that causes organ failure and death; instead, it is the body's over immune reaction that is the cause. In attempting to protect the body, the immune system overreacts to the antigen, which includes the infected cells, which causes a cytokine-storm, and the subsequent and rapid shut down of the infected individual's organ(s)' structure, leaving the body without sufficient strength or time to fight back. When the medical herbs join the body, it can slow down the immune reaction. Medical herbs benefit the physical body; they protect the cells and organism structure and mediate the immune response, allowing the T cells to kill the virus (mutated or not) internally. Such success has been achieved by the All Natural Medicine Clinic during pre-clinical trials.

This clinical study's goal is to demonstrate that the immune system can be rebuilt and retrained, using natural medicine (i.e., medical herbs), to kill the virus without causing the immune storm, and to explore the mechanism by which these medical herbs, which have been used for thousands of years for healing, achieve results.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: All Natural Medicine Clinic, LLC

Criteria

Inclusion Criteria:

A subject will be eligible for inclusion in this study if any of the following criteria apply:

• Individuals diagnosed with COVID-19 virus infection in the past 1-20 days must submit the proved metrics of COVID-19 virus marks positive during the registration;

• The age of participants is between 10-70 years old;

• The participants are received or not received conventional medication treatment, and continuing the treatment patients, could be enrolled in this clinical study;

• This clinical study is not restricted to gender, age, sex, race, and nationality;

• The participants must have reports of CBC, C3, C4, IgM, IgG, CD4/CD8, and lungs' images ready before the clinical study;

• The Participants must repeat the evaluation experiment during and at the end of the clinical study.

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

• Individuals with a prior COVID-19 virus infection that no longer shows up from COVID-19 testing;

• Children who are younger than 10-year-old, cannot control themselves to take the medical herbs on time;

• Elders whose age beyond 70-year-old, with severe underline illness;

• COVID-19 virus-infected patients who do not feel willing to take medical herbs;

• Patients diagnosed with COVID-19 virus infection cannot consistently finish the treatment courses for a specific reason;

• Patients diagnosed with COVID-19 virus infection but do not willing to share their information with the public;

• Current or past participation within a specified timeframe in another clinical trial, as warranted by this intervention's administration;

• Severe patients, when there have insufficient normal cells, can be adjusted, with pre-list diseases life-threatening.